REG - GSK PLC - GSK - second tranche of share buyback programme

GSKAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250604:nRSD2983La&default-theme=true

RNS Number : 2983L  GSK PLC  04 June 2025

Issued:  4 June 2025, London UK

 

 

GSK plc announces the second tranche of share buyback programme

 

On 24 February 2025, GSK plc ("GSK") announced the commencement of a £2
billion share buyback programme (the "Programme"), as announced in its 2024
full year results announcement published on 5 February 2025.  The Programme
is to be implemented over the period to the end of Q2 2026.

The first tranche of the Programme (of up to £0.7 billion) commenced on 24
February 2025 and completed on 3 June 2025, in accordance with its terms.

GSK announces that the second tranche of the Programme of up to £0.45 billion
will commence today.

GSK has entered into a non-discretionary agreement with Merrill Lynch
International ("MLI"), enabling GSK to buy back ordinary shares of 31¼ pence
each in GSK ("Ordinary Shares") with an aggregate value of up to £0.45
billion (the "Second Tranche"). Purchases of Ordinary Shares under the Second
Tranche are expected to commence on 4 June 2025 and to be completed by 19
September 2025.

The purpose of the Programme is to return excess capital to shareholders and
reduce the share capital of the company, and it is expected that the
implementation of the Programme will enhance earnings per share. Ordinary
Shares purchased under the Second Tranche will be held as Treasury shares.

MLI will make trading decisions in relation to the Second Tranche
independently of GSK with regard to the timing of purchases.  Any purchase of
Ordinary Shares by MLI contemplated by this announcement will be carried out
on the London Stock Exchange and/or Cboe Europe Limited through the BXE and
CXE order books.  Any purchases of Ordinary Shares by GSK from MLI under the
Second Tranche will be carried out on the London Stock Exchange.

The Second Tranche will be effected within certain pre-set parameters and in
accordance with GSK's general authority to repurchase shares and will be
conducted within the parameters prescribed by the Market Abuse Regulation
596/2014, the Commission Delegated Regulation (EU) 2016/1052 (both as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
as well as applicable laws and the regulations of the UK Financial Conduct
Authority (including Chapter 9 of the Listing Rules).

The Second Tranche will occur within the limitations of GSK's existing general
authority to repurchase up to 413,957,879 Ordinary Shares granted at its 2025
Annual General Meeting.

No repurchases will be made in the United States of America or in respect of
GSK's American Depositary Receipts.

 

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q1 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCVXLFBEQLFBBB